AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Precision Radiation Oncology Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Comprehensive treatment of recurrent and metastatic nasopharyngeal carcinoma: advances and future directions

Ming Fan1,2, Dengqun Liu2,3, Guiquan Zhu4, Yazhou Ren5, Mei Feng1,2,6( )
Department of radiation oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu, China
School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
Department of Radiation Biology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & Institute, Sichuan Cancer Preventive Center, Chengdu, China
Department of Head and Neck Oncology, West China Hospital of Stomatology, State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Sichuan University, Chengdu, China
School of Computer Science and Engineering, University of Electronic Science and Technology of China, Chengdu, China
The Third People's Hospital of Sichuan Province, Chengdu, China
Show Author Information

Abstract

The standard of care for patients with recurrent and metastatic nasopharyngeal carcinoma remains unclear. There is an urgent need to identify effective and low-toxicity treatment methods for such patients. The integration of current evidence to form an optimal treatment modality for recurrent and/or metastatic nasopharyngeal is worth exploring. In recent years, several outstanding clinical trials have emerged for the comprehensive treatment of recurrent and/or metastatic nasopharyngeal carcinoma. New evidence has been added for the local treatment of patients with metastasis. Endoscopic surgery, radiomics, and other technologies help achieve precise local treatment. Novel immunotherapeutic drugs have been approved for the treatment of patients with metastasis in China. The combination of immunotherapy, chemotherapy, and targeted therapy is promising and requires confirmation. Future studies will continue to focus on individualization and precision medicine.

Keywords

nasopharyngeal carcinomaintensity-modulated radiotherapymultimodality imaging techniquesprogrammed cell death 1 inhibitorsproton therapy

References

1
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Crossref
2

Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64-80.
Crossref Google Scholar
3

Hua Y, You R, Wang Z, et al. Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase Ⅱ trial. J Immunother Cancer. 2021;9(11):e003290.
Crossref Google Scholar
4

Chen SY, Chen MY, Rui Y, et al. Efficacy and safety of chemotherapy plus subsequent locoregional radiotherapy and toripalimab in de novo metastatic nasopharyngeal carcinoma. J Clin Oncol. 2022;40(16):40.
Google Scholar
5

Liu F, Jiang CH, Wu XW, et al. Four-year result of diffusion-weighted, MRI-guided, dose-painting radiotherapy following induction chemotherapy in patients with locally advanced recurrent nasopharyngeal carcinoma: a randomized controlled trial. J Clin Oncol. 2022;40(16):40.
Google Scholar
6

Feng M, Yin Q, Ren J, et al. Dynamic three-dimensional ADC changes of parotid glands during radiotherapy predict the salivary secretary function in patients with head and neck squamous carcinoma. Front Oncol. 2021;11:651537. https://doi.org/10.3389/fonc.2021.651537
Crossref Google Scholar
7

Zhang ZM, Zhao R, Bao Y, et al. A novel technique of endonasopharyngeal ultrasound-guided transnasopharyngeal needle aspiration in the diagnosis of submucosal recurrence of nasopharyngeal carcinoma after chemoradiotherapy. Radiother Oncol. 2021;165:14-19.
Crossref Google Scholar
8

Ng WT, Soong YL, Ahn YC, et al. International recommendations on reirradiation by intensity modulated radiation therapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2021;110(3):682-695.
Crossref Google Scholar
9

Lee A, Kitpanit S, Chilov M, et al. A systematic review of proton therapy for the management of nasopharyngeal cancer. Int J Part Ther. 2021;8(1):119-130.
Crossref Google Scholar
10

Liu YP, Wen YH, Tang J, et al. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):381-390.
Crossref Google Scholar
11

Xu H, Lu L, Lu T, et al. Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma. Head Neck. 2021;43(9):2602-2610.
Crossref Google Scholar
12

You R, Liu YP, Huang PY, et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1345-1352.
Crossref Google Scholar
13

Du C, Ni M, Jiang J, et al. Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis. Eur Arch Otorhinolaryngol. 2022;279(8):3947-3956.
Crossref Google Scholar
14

Hong S, Zhang Y, Yu G, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase Ⅲ study. J Clin Oncol. 2021;39(29):3273-3282.
Crossref Google Scholar
15

Liu GY, Li WZ, Wang DS, et al. Effect of capecitabine maintenance therapy plus best supportive care vs best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy: a phase 3 randomized clinical trial. JAMA Oncol. 2022;8(4):553-561.
Crossref Google Scholar
16

Mai HQ, Chen QY, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27(9):1536-1543.
Crossref Google Scholar
17

Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(8):1162-1174.
Crossref Google Scholar
18

Zhang Li, Yang YP, Pan JJ, et al. RATIONALE-309: updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer. J Clin Oncol. 2022;40(36):40.
Crossref Google Scholar
19

Hsu C, Lee SH, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35(36):4050-4056.
Crossref Google Scholar
20

Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol. 2018;36(14):1412-1418.
Crossref Google Scholar
21

Wang FH, Wei XL, Feng J, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase Ⅱ clinical trial (POLARIS-02). J Clin Oncol. 2021;39(7):704-712.
Crossref Google Scholar
22

Yang Y, Zhou T, Chen X, et al. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study). J Immunother Cancer. 2021;9: e003790. https://doi.org/10.1136/jitc-2021-003790
Crossref Google Scholar
23

Tang LQ, Jia GD, Lv XF, et al. Efficacy and safety of camrelizumab combined with apatinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase Ⅱ clinical trial. J Clin Oncol. 2022;40(Suppl 16):6042-6042.
Google Scholar
24

Zhao C, Miao J, Shen G, et al. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase Ⅱ clinical trial. Ann Oncol. 2019;30(4):637-643.
Crossref Google Scholar
25

Ruan X, Liang JH, Pan Y, et al. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: a multicenter, single-arm, prospective phase 2 study. Cancer. 2021;127(17):3163-3171.
Crossref Google Scholar
Precision Radiation Oncology
Volume 6 Issue 4,
December 2022
Pages 328-334
DOI: 10.1002/pro6.1181
Cite this article:
Fan M, Liu D, Zhu G, et al. Comprehensive treatment of recurrent and metastatic nasopharyngeal carcinoma: advances and future directions. Precision Radiation Oncology, 2022, 6(4): 328-334. https://doi.org/10.1002/pro6.1181

357

Views

0

Crossref

0

Scopus

Altmetrics
Received: 21 October 2022
Accepted: 16 November 2022
Published: 17 December 2022
© 2022 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Return